Compare CVS Health Corp (CVS) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Shell PLC — how do they compare? CVS Health Corp trades at $105.65 (market cap $135.48B), while Shell PLC trades at $85.25 (market cap $230.24B). The key difference: Shell PLC is the larger of the two by market cap, and Shell PLC pays the higher dividend (3.7%). Which is the better fit depends on your goals.
| CVS | SHEL | |
|---|---|---|
Market Cap | $135.48B | $230.24B |
Sector | Health | Energy |
52-Week High | $106.18 | $94.15 |
52-Week Low | $58.75 | $70.28 |
Enterprise Value | $202.02B | $282.77B |
Dividend Yield | 2.51% | 3.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
Shell (SHEL) trades at $83.98, up 2.13% in the last session, with a bullish technical signal and strong analyst consensus. Recent Q1 2026 earnings beat expectations at $2.44 EPS, while Q2 2026 is projected at $2.88. Valuation metrics appear attractive with a P/E of 13.08 and P/S of 0.92. News highlights include the ARC Resources acquisition approval and Venezuela gas field developments, indicating strategic growth initiatives.
The outlook for SHEL is positive, supported by robust cash flows, a 69% buy rating from analysts, and a consensus price target of $122.20. Risks include declining revenue trends from $381.3B in 2022 to $266.9B in 2025 and geopolitical disruptions in Middle East production. Investors may find value in its dividend yield and LNG market exposure, though macroeconomic volatility remains a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
